LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

LLY

811.14

+0.38%↑

JNJ

156.56

+0.93%↑

ABBV

192.22

+0.51%↑

NVO

81.08

+3.14%↑

UNH

318.1

+2.45%↑

Search

Arbutus Biopharma Corp

Chiusa

3.57 2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.44

Massimo

3.58

Metriche Chiave

By Trading Economics

Entrata

-12M

-25M

Vendite

190K

1.8M

EPS

-0.182

Margine di Profitto

-1,390.363

Dipendenti

44

EBITDA

-12M

-24M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+42.86% upside

Dividendi

By Dow Jones

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

31M

672M

Apertura precedente

1.57

Chiusura precedente

3.57

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Arbutus Biopharma Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 giu 2025, 20:41 UTC

Utili

Adobe Raises Outlook After 2Q Sales Beat

12 giu 2025, 23:50 UTC

Utili

Adobe Keeps Pivoting as AI Transforms Customer Needs -- Update

12 giu 2025, 23:50 UTC

Utili

Adobe Customer Demand Shifting Toward Idea Generation, CFO Says

12 giu 2025, 23:50 UTC

Utili

Adobe FireFly Products Drove Revenue Beat in 2Q, CFO Says

12 giu 2025, 23:48 UTC

Discorsi di Mercato

Gold Steady Amid Geopolitical Risks -- Market Talk

12 giu 2025, 23:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

12 giu 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

12 giu 2025, 21:26 UTC

Utili

Friedman Industries 4Q Sales $129.2M >FRD

12 giu 2025, 21:25 UTC

Utili

Friedman Industries 4Q EPS 76c >FRD

12 giu 2025, 21:11 UTC

Utili

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 giu 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

12 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 giu 2025, 20:31 UTC

Utili

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 giu 2025, 20:30 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Chime IPO: Stock Soars in Nasdaq Debut, Valuing It at Nearly $14 Billion -- Barrons.com

12 giu 2025, 20:15 UTC

Utili

Adobe Sees FY25 Rev $23.5B-$23.6B >ADBE

12 giu 2025, 20:15 UTC

Utili

Adobe Sees 3Q Rev $5.88B-$5.93B >ADBE

12 giu 2025, 20:14 UTC

Utili

Adobe Stock Pops as Earnings Beat Estimates -- Barrons.com

12 giu 2025, 20:07 UTC

Utili

Adobe Raises FY25 Rev and EPS Targets

12 giu 2025, 20:05 UTC

Utili

Adobe Sees FY Adj EPS $20.50-Adj EPS $20.70 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Experience Revenue $1.46B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Media Revenue $4.35B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe Sees 3Q EPS $4.00-EPS $4.05 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Net $1.69B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q EPS $3.94 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Experience Revenue Up 10% >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Rev $5.87B >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe Sees 3Q Adj EPS $5.15-Adj EPS $5.20 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe Sees FY EPS $16.30-EPS $16.50 >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Digital Media Revenue Up 11% >ADBE

12 giu 2025, 20:05 UTC

Utili

Adobe 2Q Adj EPS $5.06 >ADBE

Confronto tra pari

Modifica del prezzo

Arbutus Biopharma Corp Previsione

Obiettivo di Prezzo

By TipRanks

42.86% in crescita

Previsioni per 12 mesi

Media 5 USD  42.86%

Alto 5 USD

Basso 5 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arbutus Biopharma Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.255 / 3.365Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.